- 1 Type of the Paper (Article)
- 2 Molecular Insights into β-Lactams Resistance in Klebsiella pneumoniae Clinical
- 3 Isolates with a Focus on Multidrug Resistance and Virulence
- 5 Lavouisier F.B. Nogueira", Marília S. Maia", Marco A.F. Clementino", Ila F.N. Lima, Jorge L.N.
- 6 Rodrigues, Luciana V.C. Fragoso, Glairta S. Costa, Jose Q.S. Filho, Alexandre Havt, Deiziane
- 7 V.S. Costa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman, José K. Sousa* and
- 8 Aldo A.M. Lima*

4

14

- 9 # These authors contributed equally to this work.
- 10 * Corresponding authors.
- 11 **Abstract:** Klebsiella pneumoniae is associated with high resistance to antimicrobials and
- 12 is common in isolates from colonization and healthcare-associated infections (HAIs).
- 13 This study aims to develop assays to detect resistance genes belonging to the *bla* family
 - and investigate metabolic pathways in resistant isolates of *K. pneumoniae*. The genes of
- the subfamilies included were: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M
- and relevant variants of the *bla*OXA subfamily. Mass spectrometry data were acquired
- 17 on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system.
- Isolates of K. pneumoniae (N = 122) were obtained from clinical samples from 04/23/2019
- 19 to 05/29/2021. A high prevalence of resistance to penicillins, cephalosporins and
- 20 carbapenems was found among the isolates. The identified genotypic profile showed a
- 21 high prevalence of genes belonging to Ambler's classes of beta-lactamases A, B and D.
- 22 In the metabolomic study, the N-fructosyl isoleucine metabolite was identified
- 23 increased in multidrug-resistant (MDR) strains of K. pneumoniae compared to strains

susceptible to antimicrobials. In conclusion, the assays developed were efficient in detecting the main genes of the *bla* family of resistance in *K. pneumoniae*. The use of the pentose phosphate metabolic pathway suggests a beneficial regulation of bacterial growth, and colonization in MDR *K. pneumoniae* strains, with may indicate the use of this pathway as a virulence mechanism in resistant strains.

KEYWORDS: Antimicrobial resistance; multidrug-resistant; β-lactamases; qPCR; 30 molecular diagnosis; *Klebsiella pneumoniae*.

INTRODUCTION

Bacterial resistance to antimicrobial agents is a global public health problem that leads to an increase in the cost of treatment, length of stay, morbidity and mortality of hospitalized patients, especially in intensive care units (ICU).^{1,2} In this sense, understanding the emergency mechanisms of regulation and dissemination of resistance to antimicrobial agents in the pathogenesis of bacterial colonization and/or infection can be of critical importance in preventing and controlling this problem.

Klebsiella pneumoniae is a Gram-negative γ-proteobacteria bacteria, belonging to the Enterobacteriacae family, and is generally viewed as an opportunistic microorganism, carrying several virulence factors and capable of accumulating resistance genes to various classes of antimicrobials. It is commonly related to cases of colonization and/or healthcare-associated infections (HAIs) and has been identified as an etiological agent in pneumonia, urinary tract infections (UTI), soft tissue and surgical wound infections, bacteremia, and sepsis.³

It is estimated that *K. pneumoniae* is responsible for approximately 10% of all cases of HAIs, and of these, 32.8% are caused by strains resistant to multiple

antimicrobial drugs. However, studies indicate that the rate of isolated strains presenting resistance to antimicrobials has increased over the years.^{4,5}

K. pneumoniae has been associated with the ability to overcome colonization resistance imposed by the gastrointestinal microbiota⁶ and has been reported as an emerging Multidrug-Resistant microorganism of emergency priority by the World Health Organization (WHO) for the development of new therapies.⁷ Epidemiological data have demonstrated that *K. pneumoniae* can translocate from the gastrointestinal tract to other sterile sites of the same host or other patients through the fecal-oral route. What makes clear the clinical relevance of this microorganism. ⁸

One of the most likely causes of the increasingly frequent emergence of bacterial strains resistant to one or more antibiotics is the excessive and sometimes incorrect use of antimicrobials. The relatively long time required to identify the pathogen by traditional methods, as well as for the results of the antimicrobial susceptibility test (AST), forces the clinician to use broad-spectrum drugs empirically, increasing selective pressure, which ends up benefiting pathogens genetically capable of adapting to the adverse environment.^{1,9}

Possible answers to reduce the time needed to obtain a resistance profile, and to investigate new approaches in treatment, is the development of molecular methodologies, that can make the identification of resistance faster, and also be more sensitive than the traditional methodologies. And the investigation of metabolic differences between sensitive and resistant strains, that can lead to metabolites or pathways that can be used as targets for the development of new treatments and strategies for dealing with multidrug-resistant (MDR) microorganisms. 11-12

Beta-lactams are the class of antimicrobials most affected by resistance in general, which is conferred in gram-negatives, mainly by the *bla* gene family, this group of genes encodes enzymes called beta-lactamases, which can neutralize the action of beta-lactams through hydrolysis of the beta-lactam ring.¹³⁻¹⁵


In this study it was investigated the phenotype of resistance, the genotypic profile of the bla family of β -lactamases, and the metabolic differences between sensitive and MDR K. pneumoniae strains, isolated from patients admitted to the ICU in a university hospital in the city of Fortaleza-CE, Brazil.

We aim to develop a molecular assay, capable of identifying all variants of the most relevant genes of the bla family, these being: blaSHV, blaTEM, blaNDM, blaKPC, blaGES and blaCTX-M. In addition, also was included the most epidemiologically relevant variants of the bla-OXA subfamily. Thus, creating a set of primers capable of detecting the presence of hundreds of resistance genes with a reduced number of reactions. Were also investigated the main differences between the metabolites up and down regulated in sensitive and MDR strains of *K. pneumoniae*, both from the intracellular medium and the supernatant among themselves and in comparison, with the control medium.

RESULTS

Selection of bacterial samples. A total of 249 samples of Gram-negative bacteria resistant to beta lactam antimicrobials were collected from 04/23/2019 to 05/29/2021, those were identified, and the most prevalent microorganism found was *Klebsiella pneumoniae* 48.99% (122/249), been 21,8% from infections cases and 78,2% from colonization cases.

Identification of the phenotypic profile of beta-lactams resistance of *K. pneumoniae* strains. The bacteria isolates included in the study were tested against a wide range of beta-lactams drugs, and the presence of a high percentage of isolates resistant to these drugs was verified, which included <u>Penicillins</u>: ampicillin/sulbactam (92.00%) and piperacillin/tazobactam (88.46%), <u>Cephalosporins</u>: cefepime (83.02%), cefoxitin (73.68%), ceftazidime (86.54%), ceftazidime/avibactam (11.76%), ceftriaxone (83.02%), cefuroxime (90.38%) and cefuroxime axetil (81.82%) and <u>Carbapenems</u>: ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%), as shown in Figure 1.



103

104

105

106

107

Figure 1. Prevalence of *K. pneumoniae* isolates resistant to the beta-lactams evaluated (Penicillins, Cephalosporins and Carbapenems), demonstrating a phenotypic profile of resistance to multiple beta-lactams drugs, in approximately 70% of the isolates, with the exception of ceftazidime/avibactam and ertapenem.

Primers design. After selection on the platforms: Comprehensive Antibiotic

108 Resistance Data-base (CARD) and National Center for Biotechnology and Information 109 (NCBI, USA), and subsequent compilation and analysis of FASTA sequences, it was 110 possible to identify consensus sequences common to all sequences available in the 111 databases for each of the genes included in the study: blaSHV (N = 156), blaTEM (N = 112 167), blaNDM (N = 27), blaKPC (N = 208), blaGES (N = 25), and blaCTX-M (N = 144). 113 Except for the blaOXA gene, for which the most clinically relevant sequences were used (N = 203).114 115 The blaCTX-M and blaOXA genes, due to their diversity and high degree of 116 genetic variation between homologous sequences, were grouped into clades, and 117 divided into groups. the blaCTX-M gene group was named according to the 118 international standardization for this gene with the CTX-M 1like been divided into two 119 groups due to its high number or sequences and the genetic variation between them. 120 CTX-M 1.1like (N = 42), CTX-M 1.2like (N = 16), CTX-M 2like (N = 23), CTX-M 8like (N = 121 14) and CTX-M 9like (N = 49), while the blaOXA gene was divided into the OXA-23like 122 (N = 25), OXA-24/40like (N = 8), OXA-48like (N = 17) and OXA-51like (N = 153), as can 123 be seen in **Figures 2** and **3**.




Figure 2. Cladogram of the blaOXA subfamily showing the most epidemiologically relevant groups, covered by the primers developed, and the percentage of sequences identifiable by each primer in comparison with the total number of the blaOXA family (N = 441) at the time of publication of this work.




Figure 3. Cladogram with all sequences from the blaCTX-M subfamily divided into groups, illustrating the identifiable sequences, and the percentage of sequences detectable by each primer in comparison with the total number of the blaCTX-M family (N = 144) until the time of publication of this work.

A total of 14 pairs of primers were developed, which together have the capacity to detect 929 variants of resistance genes belonging to the *bla* gene family. The primer sequences for genes with conserved and non-conserved sequences can be found in **Tables 1** and **2**, respectively.

Table 1. Primer sequences for conserved genes

| Name of | Number of | Primer | Sequence | Primer |
|---------|------------|--------|------------------------|--------|
| gene | detectable | name | | size |
| blaSHV | 156 | SHV-F | ATTATCTCCCTGTTAGCCACCC | 22 |
| | | SHV-R | GTTTAATTTGCTCAAGCGGCTG | 22 |
| blaTEM | 167 | TEM-F | ACCCAGAAACGCTGGTGAAA | 20 |
| | | TEM-R | GGGGCGAAAACTCTCAAGGA | 20 |
| blaNDM | 27 | NDM-F | GAAGCTGAGCACCGCATTAG | 20 |
| | | NDM-R | CCATTTGCTGGCCAATCGTC | 20 |
| blaKPC | 208 | KPC-F | TCGCGGAACCATTCGCTAAA | 20 |
| | | KPC-R | GAATGAGCTGCACAGTGGGA | 20 |
| blaGES | 25 | GES-F | GCCCAGGAGAGAGATTACGC | 20 |
| | | GES-R | CTTGACCGACAGAGGCAACT | 20 |

Table 2. Primer sequences for non-conserved genes, divided into clades.

144

145

146

| N | Name of | | Primer | | Primer |
|----------|------------------|--------------------------|------------|----------------------|--------|
| gene | | variations detectable | name | Sequence | size |
| | blaCTX-M 1.1like | 42 | CTXM1.1L-F | GATTGCGGAAAAGCACGTCA | . 20 |
| blaCTX-M | | - | CTXM1.1L-R | TTCATCGCCACGTTATCGCT | 20 |
| | blaCTX-M 1.2like | 16 | CTXM1.2L-F | CGCCGCTGATTCTGGTCA | 18 |
| | | - | CTXM1.2L-R | TGACGATTTTAGCCGCCGAC | 20 |

| ATGGCGCAGACCCTGAAAAA | CTXM2L-F | 23 | blaCTX-M 2like | |
|-----------------------|---|---|--|--|
| CTGCCGGTTTTATCGCCCA | CTXM2L-R | | | |
| CGCTCAACACCGCGATCC | CTXM8L-F | 14 | hlaCTX-M 8like | |
| ATCCCCGACAACCCACGAT | CTXM8L-R | 11 | owerk mount | |
| CGTGGCTCAAAGGCAATACG | CTXM9L-F | 49 | hlaCTY-M 9like | |
| TCTGTTGCGGCTGGGTAAAA | CTXM9L-R | 1) | oiuCIX-WI June | |
| GCTCTAAGCCGCGCAAATAC | OXA23L-F | 24 | blaOX∆-23like | |
| TGACCTTTTCTCGCCCTTCC | OXA23L-R | 24 | ouoxx-25uxc | |
| TGCCGATGACCTTGCACATA | OXA24/40L-F | 8 | blaOXA-24/40like | |
| CCATTAGCTTGCTCCACCCA | OXA24/40L-R | | | blaOXA |
| 'GGTAGCAAAGGAATGGCAAG | OXA48L-F | 17 | hlaOXA-48like | |
| GGGCGATCAAGCTATTGGGA | OXA48L-R | 17 | OINOAA-HOIINE | |
| GATCGGCCTTGAGCACCATA | OXA51L-F | 150 | MaOVA E1111- | |
| GCCATAACCAACACGCTTCA | OXA51L-R | 153 | viaUXA-5111ke | |
| | | 153 | blaOXA-51like | |
| | CTGCCGGTTTTATCGCCCA CGCTCAACACCGCGATCC ATCCCCGACAACCCACGAT CGTGGCTCAAAGGCAATACG TCTGTTGCGGCTGGGTAAAA GCTCTAAGCCGCGCAAATAC TGACCTTTTCTCGCCCTTCC TGCCGATGACCTTGCACATA CCATTAGCTTGCTCCACCCA CGGTAGCAAAGGAATGGCAAG GGGCGATCAAGCTATTGGGA GATCGGCCTTGAGCACCATA | CTXM2L-R CTGCCGGTTTTATCGCCCA CTXM8L-F CGCTCAACACCGCGATCC CTXM8L-R ATCCCCGACAACCCACGAT CTXM9L-F CGTGGCTCAAAGGCAATACG CTXM9L-R TCTGTTGCGGCTGGGTAAAA OXA23L-F GCTCTAAGCCGCGCAAATACC OXA23L-R TGACCTTTTCTCGCCCTTCC OXA24/40L-F TGCCGATGACCTTGCACATA OXA24/40L-R CCATTAGCTTGCTCCACCCA OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-R GGGCGATCAAGCTATTGGGA OXA51L-F GATCGGCCTTGAGCACCATA | 23 CTXM2L-R CTGCCGGTTTTATCGCCCA 14 CTXM8L-F CGCTCAACACCGCGATCC 14 CTXM8L-R ATCCCCGACAACCCACGAT 49 CTXM9L-F CGTGGCTCAAAGGCAATACG CTXM9L-R TCTGTTGCGGCTGGGTAAAA OXA23L-F GCTCTAAGCCGCGCAAATAC OXA23L-R TGACCTTTTCTCGCCCTTCC OXA24/40L-F TGCCGATGACCTTGCACATA OXA24/40L-R CCATTAGCTTGCTCCACCCA OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-R GGGCGATCAAGCTATTGGGA OXA51L-F GATCGGCCTTGAGCACCATA | blaCTX-M 2like 23 CTXM2L-R CTGCCGGTTTTATCGCCCA CTXM8L-F CGCTCAACACCGCGATCC CTXM8L-R ATCCCCGACAACCCACGAT CTXM9L-F CGTGGCTCAAAGGCAATACG blaCTX-M 9like 49 CTXM9L-F CGTGGCTCAAAGGCAATACG CTXM9L-R TCTGTTGCGGCTGGGTAAAA OXA23L-F GCTCTAAGCCGCGCAAATAC OXA23L-R TGACCTTTTCTCGCCCTTCC OXA23L-R TGCCGATGACCTTGCACATA blaOXA-24/40like 8 OXA24/40L-F TGCCGATGACCTTGCACATA OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-F GGTAGCAAAGGAATGGCAAG OXA48L-R GGGCGATCAAGCTATTGGGA OXA48L-R GGGCGATCAAGCTATTGGGA OXA51L-F GATCGGCCTTGAGCACCATA |

In silico primers validation. The parameters obtained for each primer after analysis using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite (SMS): PCR Primer Stats software are available in **Table 3**.

147

148

149

150

151

Table 3. Parameters obtained by *in silico* validation of the developed primers.

| Gene | Primer name | Tm (C°) | GC% | Self | Self 3' | Produt |
|-----------------|-------------|---------|------|-----------------|-----------------|--------|
| | | ` , | | complementarity | complementarity | length |
| blaSHV | SHV-F | 59,2 | 50,0 | 3 | 0 | 70 |
| 014511 v | SHV-R | 59,3 | 45,4 | 5 | 3 | 70 |
| blaTEM | TEM-F | 60,1 | 50,0 | 4 | 0 | 110 |

| TEM-R | 59,9 | 55,0 | 2 | 1 | |
|-------------|---|--|---|--|---|
| NDM-F | 59,3 | 55,0 | 5 | 1 | 86 |
| NDM-R | 60,1 | 55,0 | 6 | 2 | |
| KPC-F | 60,3 | 50,0 | 4 | 2 | 128 |
| KPC-R | 60,3 | 55,0 | 5 | 1 | 120 |
| GES-F | 59,9 | 60,0 | 3 | 2 | 94 |
| GES-R | 59,9 | 55,0 | 3 | 2 | _ |
| CTXM1.1L-F | 59,7 | 50,0 | 4 | 1 | 87 |
| CTXM1.1L-R | 60,1 | 50,0 | 4 | 2 | |
| CTXM1.2L-F | 60,1 | 61,1 | 3 | 2 | 90 |
| CTXM1.2L-R | 61,0 | 55,0 | 3 | 3 | _ |
| CTXM2L-F | 60,5 | 50,0 | 4 | 0 | 155 |
| CTXM2L-R | 60,7 | 57,8 | 4 | 1 | |
| CTXM8L-F | 61,5 | 66,6 | 4 | 2 | 197 |
| CTXM8L-R | 60,9 | 57,8 | 3 | 2 | |
| CTXM9L-F | 59,9 | 55,0 | 3 | 2 | 180 |
| CTXM9L-R | 60,1 | 50,0 | 3 | 0 | |
| OXA23L-F | 60,0 | 55,0 | 4 | 0 | 129 |
| OXA23L-R | 59,9 | 55,0 | 2 | 0 | |
| OXA24/40L-F | 59,7 | 50,0 | 4 | 2 | 177 |
| DXA24/40L-R | 60,0 | 55,0 | 4 | 0 | |
| OXA48L-F | 59,8 | 52,3 | 3 | 0 | 183 |
| OXA48L-R | 59,8 | 55,0 | 4 | 0 | |
| C/LITEL IX | | | | | |
| OXA51L-F | 59,8 | 55,0 | 4 | 2 | 199 |
| | NDM-R KPC-F KPC-R GES-F GES-R CTXM1.1L-F CTXM1.2L-F CTXM1.2L-F CTXM2L-F CTXM2L-R CTXM8L-F CTXM8L-F CTXM8L-R CTXM9L-F CTXM9L-F CTXM9L-F | NDM-R 60,1 KPC-F 60,3 KPC-R 60,3 GES-F 59,9 GES-R 59,9 CTXM1.1L-F 59,7 CTXM1.2L-F 60,1 CTXM1.2L-R 61,0 CTXM2L-F 60,5 CTXM2L-F 60,7 CTXM8L-F 61,5 CTXM9L-F 59,9 CTXM9L-R 60,1 OXA23L-F 60,0 OXA24/40L-F 59,7 OXA24/40L-R 60,0 | NDM-R 60,1 55,0 KPC-F 60,3 50,0 KPC-R 60,3 55,0 GES-F 59,9 60,0 GES-R 59,9 55,0 CTXM1.1L-F 59,7 50,0 CTXM1.2L-F 60,1 50,0 CTXM1.2L-R 61,0 55,0 CTXM2L-F 60,5 50,0 CTXM2L-R 60,7 57,8 CTXM8L-F 61,5 66,6 CTXM8L-R 60,9 57,8 CTXM9L-R 60,1 50,0 CXA23L-F 60,0 55,0 CXA23L-R 59,9 55,0 CXA24/40L-F 59,7 50,0 DXA24/40L-R 60,0 55,0 | NDM-R 60,1 55,0 6 KPC-F 60,3 50,0 4 KPC-R 60,3 55,0 5 GES-F 59,9 60,0 3 GES-R 59,9 55,0 3 CTXM1.1L-F 59,7 50,0 4 CTXM1.2L-F 60,1 61,1 3 CTXM1.2L-R 61,0 55,0 3 CTXM2L-F 60,5 50,0 4 CTXM2L-F 60,5 50,0 4 CTXM2L-R 60,7 57,8 4 CTXM8L-F 61,5 66,6 4 CTXM9L-R 60,9 57,8 3 CTXM9L-R 60,1 50,0 3 CTXM9L-R 60,1 50,0 3 CXA23L-R 59,9 55,0 2 DXA24/40L-F 59,7 50,0 4 DXA24/40L-R 60,0 55,0 4 | NDM-R 60,1 55,0 6 2 KPC-F 60,3 50,0 4 2 KPC-R 60,3 55,0 5 1 GES-F 59,9 60,0 3 2 GES-R 59,9 55,0 3 2 CTXM1.1L-F 59,7 50,0 4 1 CTXM1.2L-F 60,1 50,0 4 2 CTXM1.2L-F 60,1 61,1 3 2 CTXM1.2L-R 61,0 55,0 3 3 CTXM2L-F 60,5 50,0 4 0 CTXM2L-R 60,7 57,8 4 1 CTXM8L-F 61,5 66,6 4 2 CTXM9L-F 59,9 55,0 3 2 CTXM9L-R 60,1 50,0 3 0 OXA23L-F 60,0 55,0 4 0 OXA24440L-R 60,0 55,0 4 0 |

Testing, optimization, and standardization of *in vitro* reactions. All primers were tested using positive controls developed *in house*, and it was possible to verify that the ideal annealing temperature (Ta) for the developed primer pairs was 61°C, except for the primer referring to the *blaNDM* gene, for which the ideal Ta was 64°C. The reactions were then evaluated for their specificity and stability by checking the Melting temperature (Tm). The melting curves are available in the supplementary material Figure S1.

Efficiency curve It was found that all tested primers presented an efficiency rate \geq 93.21 and \leq 101.28%, $R^2 \geq$ 0.99, and detection limit between \approx 2 and \approx 13 copies/ μ L as shown in Table 4.

Table 4. Results of the efficiency curves of the developed primers.

| Gene name | Efficiency | Correlation | Threshold | Detection limit | Melting Peak |
|------------------|------------|------------------|-----------|-----------------|--------------|
| Gene name | (%) | coefficient (R2) | Threshold | (Copies/μL) | (Tm°C) |
| blaSHV | 96,15 | 0,992 | 0,60 | ≈2 | 86,7 |
| blaTEM | 95,32 | 1,000 | 0,70 | ≈2 | 81,5 |
| blaNDM | 99,90 | 0,999 | 0,48 | ≈2 | 85,7 |
| blaKPC | 100,44 | 0,992 | 0,24 | ≈2 | 85,7 |
| blaGES | 100,21 | 0,997 | 0,27 | ≈2 | 81,7 |
| blaCTX-M 1.1like | 95,75 | 0,999 | 0,40 | ≈13 | 84,3 |
| blaCTX-M 1.2like | 100,82 | 0,994 | 0,32 | ≈13 | 83,2 |
| blaCTX-M 2like | 98,09 | 0,998 | 0,30 | ≈2 | 86,4 |
| blaCTX-M 8like | 95,32 | 1,000 | 0,10 | ≈13 | 88,4 |
| blaCTX-M 9like | 97,82 | 0,996 | 0,10 | ≈2 | 89,0 |

| blaOXA-23like | 99,51 | 1,000 | 0,15 | ≈2 | 78,4 |
|------------------|--------|-------|------|-----|-------|
| blaOXA-24/40like | 101,82 | 0,988 | 0,15 | ≈13 | 78,7 |
| blaOXA-48like | 93,21 | 1,000 | 0,20 | ≈13 | 80,29 |
| blaOXA-51like | 95,51 | 0,993 | 0,55 | ≈2 | 82,0 |

Identification of the genetic resistance profile of *K. pneumoniae* isolates. The 122 *K. pneumoniae* isolates were tested against the 14 pairs of primers developed, and it was possible to verify a high prevalence of beta-lactam resistance genes among the isolates analyzed. The most prevalent genes detected were, respectively: *bla*KPC (95.90%); *bla*SHV (94.26%); *bla*CTX-M 1.2*like* (88.52%); *bla*CTX-M 2*like* (83.61%); *bla*CTX-M 1.1*like* (80.33%); *bla*TEM (80.33%); *bla*NDM (33.61%); *bla*OXA-23*like* (28.69%); *bla*GES (20.49%); *bla*OXA-51*like* (15.57%); *bla*CTX-M 9*like* (13.93%); *bla*CTX-M 8*like* (12.30%); *bla*OXA-24/40*like* (11.48%) *and bla*OXA-48*like* (3.28%). The results can be seen in Figure 4A, grouped according to Ambler's classification.

It is important to note that not all variants of each group of genes analyzed belong to a single class in the Ambler's classification, such as *bla*TEM and *bla*SHV genes, where not all variants have activity as extended spectrum beta-lactamases (ESBL) for example, however, due to the grouping of all sequences in a single primer, the separation of these sequences into other groups would be impossible, so the grouping of genes was carried out globally in a way that covered the mains classification of the subfamily in question.

Through the data obtained by the qPCR reactions developed, it was also possible to verify that the isolates analyzed during this study had the presence of

several genes belonging to the *bla* family accumulated, with values varying from 3 to 12 of the tested genes, present per isolate, as shown in **Figure 4B**.

183

184

185

186

187

188

189




Figure 4. (A) Prevalence of beta-lactams resistance genes among the analyzed isolates, grouped according to the Ambler classification. **(B)** The percentage of *K. pneumoniae* isolates showing accumulation of genes encoding beta-lactamases belonging to the *bla* family.

Comparisons of metabolomic profiles of *K. pneumoniae* isolates. In total, 241 metabolites were identified in positive mode and 116 metabolites identified in negative mode. Among these, 309 metabolites were identified by combining data from both acquisition modes (positive and negative) without redundancy. The principal component analysis (PCAs) and the heatmap analysis between the metabolites in supernatant of susceptible *K. pneumoniae* versus the control culture medium showed complete separation of the main vectors of the PCA plots and differential upregulation or downregulation between the two experimental groups (Figure 5). Among these metabolites, 25 were upregulated or downregulated. Interestingly, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased in supernatant derived from susceptible *K. pneumoniae* (Figures S2, S3 and S4). Similar findings were detected between MDR *K. pneumoniae* strains and control culture medium (Figures S5, S6 and S7).




Figure 5. Comparison between susceptible *K. pneumoniae* supernatants (Sens) versus culture media. **(A)** Plot of the principal component analysis (PCAs) and **(B)** the heatmap of the comparison of metabolites between the supernatant of susceptible *K. pneumoniae* versus the control culture media.

The principal component analysis (PCAs) and the heatmap analysis of metabolites in supernatants from *K. pneumoniae* MDR versus susceptible isolates exhibited complete separation of the main vectors of the PCA plots (**Figure 6A**) and differences on levels of metabolites (**Figure 6B**). The analysis of deregulated metabolites between *K. pneumoniae* MDR versus susceptible isolates showed increased N-fructosyl isoleucine in the MDR *K. pneumoniae* isolates (p<0.05, **Figure 6C**).




Figure 6. Comparison of supernatants from *K. pneumoniae* MDR versus susceptible (Sens). **(A)** Plots of the principal component analysis (PCAs) and **(B)** the heatmap of the comparison of metabolites between the supernatant of *K. pneumoniae* MDR versus

susceptible (Sens). **(C)** Plots of dysregulated metabolites between supernatants of *K. pneumoniae* MDR and susceptible.

Analysis of the intracellular metabolites of susceptible versus MDR K. pneumoniae showed differences in the PCAs vectors (**Figure 7A**), heatmap (**Figure 7B**). and increased N-fructosyl isoleucine levels in the MDR K. pneumoniae isolates (p<0.05, **Figure 7C**). **Figure 8** shows the PCAs and heatmap plots of supernatant from sensitive and MDR K. pneumoniae.




Figure 7. Comparison of Intracellular media of *K. pneumoniae* MDR versus susceptible (Sens). **(A)** Principal Component Analysis (PCAs) plots and **(B)** Heatmap of the Intracellular Environment of *K. pneumoniae* MDR and susceptible. **(C)** Plots of dysregulated metabolites between the intracellular media of *K. pneumoniae* MDR and susceptible.




Figure 8. Comparison of *K. pneumoniae* Multidrug-Resistant (MDR) supernatants versus culture media. (A) Principal component analysis (PCAs) plots and (B) Heatmap of the supernatant of *K. pneumoniae* susceptible and MDR. Observe the separation of the main vectors of the (PCAs) plots and details of the differences in the heatmap between the two experimental groups.

DISCUSSION

During the period analyzed in the study, 249 bacterial isolates resistant to two or more classes of antimicrobials used in TSA were identified. Of these resistant isolates, 48.99% (122/249) belonged to the species *Klebsiella pneumoniae*, being this microorganism the most prevalent among those identified.

This data is consistent with what is seen in Egypt, where when evaluating 186 samples from Cairo hospitals, *K. pneumoniae* was found as the main gram-negative bacterial agent representing 40.9% (76/186) of the identified microorganisms, and

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

among these isolates obtained, a high prevalence of resistance to beta-lactams, quinolones, and sulfonamides was identified (89.4%, 89.4% and 87.1%) respectively.¹⁶ The phenotypic profile of the K. pneumoniae isolates analyzed in the present study demonstrated high levels of resistance to the beta-lactams drugs tested in all classes evaluated (penicillins, cephalosporins and carbapenems). Although the resistance profile of strains may vary depending on the test location and the conditions to prevent spread, the resistance to beta-lactams among Enterobacteriaceae is known to be high, as demonstrated in a study carried out in Brazil, with samples of human and veterinary origin where 62.85% and 54.28% of Enterobacteriaceae isolated were resistant to amoxicillin/clavulanate and cefazolin respectively. 17 In studies carried out in Egypt, evaluating isolates of K. pneumoniae from food sources, and in Tunisia and Iran evaluating isolates from hospital samples, the presence of high resistance to beta-lactams can be verified for ampicillin/sulbactam (95.5%), (93%), (95.5%),ceftazidime cefoxitin cefotaxime $(93.2\%)_{i}$ amoxicillin/clavulanate (86.4%), ertapenem (90.9%) and temocillin (84.0%).^{18, 19, 20} Likewise, in a study carried out with 102 isolates obtained from two Portuguese hospitals, the presence of resistance rates > 90% was verified for all beta-lactam drugs tested, except for cephalosporins: cefoxitin (40.2%), cefotetan (68.6%) and carbapenems: ertapenem (23.5%), imipenem (32.4%), meropenem (34.3%) and doripenem (33.3%).²¹ This result is consistent with that found in this study, where the beta-lactam drugs that showed a lower resistance rate belonged to the same classes mentioned, namely: cefoxitin (73.68%), ceftazidime/avibactam (11.76%), ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%).

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

Resistance to beta-lactams is conferred in Gram-negatives mainly by genes belonging to the bla family. This group of genes is composed of dozens of subfamilies and hundreds of genetic subvariants in each family, the molecular panel developed managed to encompass some of the most predominant and clinically relevant subfamilies among clinical isolates, identified in several studies, namely: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M and blaOXA.22-24 After analysis using the Primer-BLAST® (NCBI, USA) and Primer Stats Sequence Manipulation Suite (SMS) software, it was verified that the developed primers have specificity for the sequences used in the alignment, melting temperature (Tm) between 59 29 °C and 61.55 °C, GC% concentration varying between 45.45% and 66.67% in addition to having complementary base numbers ≤ 6 in the analysis of dimer and hairpin formation. The values obtained for these parameters therefore demonstrate that they are compatible with those obtained in reference studies.^{25–27} Due to the high number of sequences included in the development of primers, many of the alternatives obtained through Primer-BLAST® (NCBI, USA) did not meet the stability requirements regarding the formation of secondary structures (selfannealing and hairpins), In order to choose the options with the best performance in relation to these parameters, the GC clamp was relaxed so that the primers SHV-F, SHV-R, CTXM1.2L-R and CTXM2L-R obtained 4 G or C residues within the last 5 nucleotides of the 3' end, the primers CTXM9L-R and CTXM2L-F did not present C or G residues within the last 5 nucleotides of the sequence. This fact could lead to the formation of strong bonds and increase the Tm value in primers with more than 3 terminal GC residues, and cause inhibition of amplification due to the presence of weak bonds when there is an absence of terminal

CG ^{28,29}. Such changes, however, were not evident when the primers were tested *in* vitro.

The variety of sequences detectable by the developed primers makes in vitro validation using positive controls for all sequences virtually impossible. In silico analysis allowed the evaluation of all tested sequences quickly, cheaply and constantly, since the developed primers can be tested against new variants of the target genes.^{26–28}

In vitro analyzes were carried out using SYBR Green master mix, the melting curve was therefore used as a parameter to evaluate the specificity of the reactions. And it was verified that for all tested primers a single melting peak was found, indicating the formation of a single amplicon. And excluding the presence of secondary structures (primer dimers and hairpins).

The analysis of the melting curve and Tm is considered fundamental to test the specificity of reactions that use SYBR Green as an amplification indicator, because unlike reactions that use specific probes, which emit fluorescence only when the reaction occurs at the expected target. The SYBR Green works by binding to any double-stranded fragment formed, thus emitting fluorescence. Therefore, only by analyzing the melting curve and the specific Tm of the amplicon is it possible to determine whether the reaction was successful.^{29–31}

The efficiency curve and its parameters were used to evaluate the performance of qPCR reactions, by checking how efficiently the targets were amplified in each PCR cycle.^{32, 33} When evaluating the activity of primers in qPCR reactions using the efficiency curve, it was found that all primers analyzed in this study presented efficiency values >90% and <110% and correlation coefficients (R²) >0.9, thus being in accordance with the parameters presented in reference documents present in the

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

literature.³³ It was also possible to verify a high detection capacity even at low concentrations of genetic material since the detection limit obtained varied between ≈2 and ≈13 copies/µL of the target gene used as control. Several studies report the growth in the prevalence of the blaKPC gene, with this being the most detected carbapenemase worldwide. The values found vary according to the location. The main variant of the blaKPC gene detected is blaKPC-2, with prevalence values varying from 1.2% to 51.6% among enterobacteria in studies carried out in the United States of America and China respectively.^{34, 35} This gene is found more frequently in isolates of K. pneumoniae, many studies report high prevalence rates in this species ranging from 17.2% to 64.6%. 4, 35, 36, 37 In a study conducted in an intensive care unit in the northeast region of Brazil, it was shown that of 25 isolates of K. pneumoniae obtained during the research, 100% exhibited the presence of the blaKPC gene. 38 The values found in this paper for the blaKPC gene may reflect the fact that the primer developed detected all variants of the gene, as well as the higher rates of resistance usually found in intensive care unities (ICU).³⁹ The results found in this work are in agreement with other studies performed at the northeast of Brazil³⁸, what can represent an endemic presence of the blaKPC gene among *K. pneumoniae* isolates in this Brazilian region. The blaTEM and blaSHV genes were the first ESBL identified, and together with the blaCTX-M subfamily of genes are considered the most prevalent ESBL's. These genes are widely distributed among enterobacteria; in a study carried out in Sudan, the blaTEM, blaCTX-M and blaSHV genes were identified in 86.0%, 78.0% and 28.0% respectively.40

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

In a work carried out in ICUs in Chile, it was possible to verify the presence of these genes with prevalence rates of 81.0%, 84.7% and 73.0% for blaSHV, blaCTX-M-1 and blaTEM, where a higher prevalence of the blaSHV gene was found when compared to the study carried out in Sudan.41 In Brazil, it is also possible to verify the presence of high prevalence rates of these genes among K. pneumoniae isolates from ICU, with studies indicating rates of 100%, 96% and 72% for blaTEM, blaSHV and blaCTX-M1 respectively. 38 These results agree with those evidenced in this study for the K. pneumoniae isolates tested. The blaNDM gene is considered the second most prevalent carbapenemase producing gene in the world, behind only the blaKPC gene. In this study, the presence of the metallo beta-lactamase NDM gene was verified in (33.61%) of the isolates. Similar results were evidenced in China, where the presence of this gene was verified in 35.7% of 935 carbapenem-resistant enterobacteria tested.³⁴ The prevalence found in this study for the blaNDM gene is still below what was found in other studies carried out in Brazil in the states of São Paulo and Sergipe, where the authors found a prevalence of 70 and 50% respectively in K. pneumoniae isolates. 42, 43 Regarding oxacillinases, a low prevalence of the blaOXA-48like gene was observed (3.28%). This gene may be present in all Enterobacteriaceae; however, it is more prevalent in strains of *K. pneumoniae*.²¹ The values found in the literature for the presence of this gene in Enterobacteriaceae are very divergent, with marked variations related to the location of the analysis, these values vary from 7.3% in China to 83.3% in Morocco.^{34, 44} In a study conducted in Brazil where 4,451 isolates of Enterobacteriaceae were analyzed, the

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

blaOXA-48like gene was detected in only 2.5% of the isolates tested.45 In this way, the result obtained is compatible with what was previously identified in Brazil, and close to what is seen in China. The presence of variants of the blaOXA gene (bla-OXA-51like (15.57%), blaOXA-24/40like (11.48%) and blaOXA-23like (28.69%)) was also observed in the isolates tested, these genes were long considered exclusive to strains of Acinetobacter baumannii, however studies have demonstrated the presence of these genes in other Enterobacteriaceae, including K. pneumoniae. 46 Results regarding the prevalence of these genes in strains of K. pneumoniae are still scarce, however, in a study conducted in Bahrain in the Persian Gulf, the blaOXA-51 and blaOXA-23 genes were identified respectively in 45.8% and 41.6%. % of *K. pneumoniae* isolates analyzed.⁴⁷ It is believed that many of the beta-lactamases that today can be found contained in mobile genetic elements had their origin in chromosomes of other bacteria, as occurred with the SHV type variants that derived from the K. pneumoniae chromosomal SHV-1, and the CTX-M type variants that appear to have originated from the chromosomal CTX-M of Kluyvera spp²¹. This change in the presentation of these genes, from chromosomal to mobile elements, may explain the appearance of genes such as chromosomal blaOXA present in A. baumannii strains on plasmids widespread in other species. It was possible to verify the presence of isolates presenting multiple genes coding for beta-lactamases, from 3 to 12 of the genes analyzed. Studies point to a high prevalence among Enterobacteriaceae of the accumulation of genes from the bla family, mainly genes belonging to ESBL, OXA beta-lactamases and carbapenemases such as

blaKPC and blaNDM. This phenomenon is more evident in hospital environments

where selective pressure favors microorganisms carrying resistance genes and where there is a high rate of sharing of these genes.^{48,49}

Investigations into metabolomic modulation in *K. pneumoniae* have demonstrated a promising area for understanding resistance to antimicrobial agents, developing new therapies, and for studying bacterial virulence. For example, significant inhibition of the pentose phosphate pathway, citrate cycle, amino acid and nucleotide metabolism was observed to be beneficial during treatment of MDR *K. pneumoniae* using the bacteriophage-polymyxin combination, showing the potential for new therapeutic targets and pathways metabolic processes to improve the effectiveness of treatment with available antimicrobial agents.^{50,51}

This study is in accordance with others that highlighted the importance of the pentose phosphate pathway in MDR *K. pneumoniae* strains.⁵⁰ This finding was present in both media, supernatant and intracellular in MDR isolates, compared with *K. pneumoniae* isolates susceptible to antimicrobial agents. The significant presence of the metabolic N-fructosyl isoleucine (C12H23NO7; MW: 293.316) in the supernatant and intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose degradation enzyme gene (*frwC*; fructose-specific phosphotransferase system), which is involved in regulating bacterial growth, virulence and overcoming colonization resistance due to the use of alternative carbon source from fructose.^{52, 53}

Metabolomics has proven to be a promising approach in the study of antimicrobial resistance. Its use allows for the comprehensive investigation of metabolic changes associates with different resistance mechanisms, such as alternative energy-obtaining pathways, modifications that alter the cell wall, communication

between bacterial cells, and changes in the colonization capacity of these microorganisms.^{54, 55}

The identification of these metabolic differences plays an important role in the Discovery of new therapeutic targets and strategies for investigating the reversal of resistance in these pathogens.⁵⁵⁻⁵⁷ The combination of genetic and metabolomic techniques therefore contributes to a comprehensive view of resistance mechanisms in bacteria. ^{56,57}

The presence of N-fructosyl isoleucine in resistant strains, and the metabolic benefit that its presence appears to generate in increasing colonization capacity, together with the selective pressure found in ICU environments due to the constant use of antimicrobials may be related to the high rates of resistant isolates disseminated among patients in this environment.

The metabolic evaluation in turn points to a metabolic advantage in resistant strains compared to sensitive ones, which goes beyond the resistance capacity itself.⁵⁸

This study has some limitations, such as the exploration of only *bla* family genes, limiting a broader understanding of resistance mechanisms to antimicrobial agents. On the other hand, it presents a broad methodology for exploring the important *bla* family genes most associated with resistance to beta-lactams in *K. pneumonia*. The metabolic findings showed a specific indication that suggests an association with virulence and better proteomic studies will be necessary to associate with potential mechanisms of resistance to antimicrobial agents. Furthermore, additional preclinical studies will be necessary to determine and more specifically validate the virulence associated with the pentose phosphate pathway in *K. pneumoniae*.

CONCLUSIONS

The results of this work show the high prevalence of resistance to antimicrobial agents in isolates of *K. pneumoniae* within the hospital environment, and that this phenotypic pattern exhibited a great concern as it limits the therapeutic options available, directly implicating the patient's prognosis.

The assays developed were within the quality criteria for qPCR reactions using SYBR Green master mix and were efficient in detecting the beta-lactams resistance genes from the *bla* family evaluated in this study. The genotypes of the *bla* genes obtained are relevant and worrying for the local hospital scenario, and compatible with the identified phenotypic profile.

The identification of the metabolic N-fructosyl isoleucine in the supernatant and intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose degradation enzyme gene, which is involved in regulating bacterial growth, virulence and overcoming resistance to colonization due to the use of an alternative carbon source from fructose.

MATERIALS AND METHODS

Obtaining bacterial isolates and identification. For the following study, samples were collected as part of the clinical investigation of patients admitted to the ICU of a tertiary care health unit in the city of Fortaleza-CE. Were included in the work those microorganisms that were identified as gram-negative bacteria, resistant to two

or more groups of antimicrobial agents, including subclasses of β -lactams, fluoroquinolones and aminoglycosides.

The bacterial isolates were identified and tested for their susceptibility to antimicrobials using the automated VITEK® 2 Compact method (BioMérieux, Marcy l'Etoile, France), according to the manufacturer's recommendations. Minimum inhibitory concentrations were interpreted according to the Clinical and Laboratory Standards Institute (CLSI). For quality control of sensitivity tests, strains from the American Type Culture Collection (ATCC) were used. Specimens that had a resistance profile that fit the research objectives were included in the study.

Extraction of bacterial DNA. To extract the genetic material, the Wizard Genomic DNA Purification extraction and purification kit (Promega, Madison, USA) was used, according to the manufacturer's recommendations.

After extraction, all samples were then quantified by spectrophotometry using the NanoDropTM 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and stored in a -80°C freezer until used in the experiments.

Selection of genes used in the study and obtaining FASTA sequences. For greater coverage of the genetic profile of resistance to β-lactams in gram-negatives, genes with relevant prevalence epidemiology, belonging to the *bla* gene family, were part of the study, and these included the genes: *blaSHV*, *blaTEM*, *blaNDM*, *blaKPC*, *blaGES*, *blaCTX-M* and *blaOXA*. The sequences used were obtained through the Comprehensive Antibiotic Resistance Database (CARD) and National Center for Biotechnology information (NCBI) platforms, which compiles and organizes the

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

resistance gene sequences available in GenBanck, the list of identifiable sequences is available in the supplementary material Text S1. Primer design. To design the primers, all variant sequences of each gene included in the study available on the CARD and NCBI platforms were gathered, the sequences were aligned using the Clustal Omega software, and the alignments were analyzed using the SnapGene software. Consensus regions with homology ≥95% were selected and these were used to design the primers using the Primer Blast platform from the National Center for Biotechnology and Information (NCBI, USA). The consensus sequences obtained is available in the supplementary material Text S2. Genes with few conserved regions, for which it was not possible to obtain consensus sequences with homology ≥95%, were separated into clades, and primers were then designed for the sequences by phylogenetic grouping, complying with a minimum of 95% similarity. In silico validation of the developed primers. All primers developed were validated in silico regarding their specificity, structure, formation of primer-dimers and hairpins using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite (SMS): PCR Primer Stats platforms. Testing, optimization, and standardization of primers. The reactions were standardized with the use of positive controls developed in-house, through amplification of genetic material, isolation, and purification of amplicons, originating from isolates phenotypically resistant to beta-lactams, and negative control (water

DNase/RNase free). They were carried out using a CYBR Green master mix (Promega,

Madison, USA), the initial results were evaluated regarding the melting temperature (Tm), to confirm the specificity of the amplicons.

To determine the most efficient qPCR conditions, to reduce the existence of non-specificity and facilitate the interpretation of the results, the concentration gradient and annealing temperature (Ta) of the primers were performed. The qPCR reaction conditions included a hot start step at 95°C for 2 minutes, followed by 35 cycles consisting of a denaturation step for 15 seconds at 95°C, and an annealing/extension step for 1 minute at Ta. specific to each primer, all reactions went through a final melting curve step, with a temperature variation of 60 to 95°C with an increase of 0.05°C/sec.

A 9-point efficiency curve was performed with a dilution factor of 1:8, for each primer developed, with concentrations ranging from \approx 27,438,596 to \approx 2 (copies/ μ L), through this procedure it was possible to determine the values of threshold, evaluate the efficiency (%), the correlation coefficient (R²) and the limit of detection of each primer.

Detection of resistance-related genes by molecular biology. The *K. pneumoniae* isolates obtained in the study were tested against the developed primers. Melting curve analysis of all reactions was used to evaluate the specificity of the results of the isolates in comparison to the specific melting temperature (Tm) of the positive control.

Preparation of *K.* pneumoniae samples for metabolomic evaluation. Isolates of *K. pneumoniae* susceptible and multidrug resistant to antimicrobial agents obtained in this work were submitted for metabolomic analysis. For this experiment, seven samples of the culture supernatant were designed: one sample of the culture medium, two samples of the culture supernatant of susceptible *K. pneumoniae* (biological

replicates), four samples of the culture supernatant of multidrug-resistant *K. pneumoniae* (MDR) for untargeted metabolomics determination and analysis. Samples of the intracellular medium of the *K. pneumoniae* culture, two samples of susceptible *K. pneumoniae* (biological replicates) and four samples of MDR *K. pneumoniae* were also used for untargeted metabolomic analysis. Technical replicates were performed for susceptible media and samples to allow for a pilot statistical comparison.

Methodology for extracting *K. pneumoniae* culture supernatant. To 200 μL of *K. pneumoniae* culture medium or control medium, 800 μL of 80% methanol was added at -20 °C. The samples were vortexed and incubated at -20 °C for 2 hours for protein precipitation. The samples were centrifuged for 10 min at 4°C at 10,000 g (Benchtop refrigerated centrifuge 10k RPM Eppendorf) and the supernatants were transferred to new tubes. The samples were dried under vacuum (Speed Vac Thermo fisher) for approximately 4-5 hours. Dried samples were redissolved in 100 μL of 0.1% formic acid in water containing Metabolomics QReSS labeled heavy standards diluted 100X. (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). A quality control (QC) was done, combining 10 μL of each sample. After the QC test in the mass spectrometer, the samples were diluted 10x to be analyzed. The injection volume of each sample was 10 μL per ionization mode.

Methodology for extractions from the intracellular medium of K. pneumoniae culture. To each tube, 750 μ L of cold chloroform:methanol (2:1) mixture at -20 °C was added, vortexed and transferred to tubes reinforced with a ball beater. Cells were disrupted in a bead beater with steel balls for 3 min at an intensity of 5 (Bead Ruptor Elite Omni International Material). The tubes were shaken vigorously for 30 min at 4°C in a temperature-controlled thermal shaker (Thermomixer Eppendorf). 400 μ L of water

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

was added, shaken vigorously, and centrifuged for 10 min at 10,000 rpm (Benchtop refrigerated centrifuge 10k RPM Eppendorf) for phase separation. The upper aqueous/methanolic phase was saved as a mixture of soluble metabolites and transferred to Eppendorf tubes. Soluble metabolites were dried under vacuum for 3-4 h (Speed Vac Thermo Fisher). Before running, samples were reconstituted in 100 μL of 0.1% formic acid in water containing 100X diluted Metabolomics QReSS labeled heavy standards (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The QC sample was prepared with 10 µL of each sample. The injection volume of each sample was 10 µL. Analysis by Ultra Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry (UPLC-MS/MS) of metabolites. MS data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Soluble metabolites were separated using a Waters BEH C18 column (100 x 2.1 mm, 1.9 µm) operated at 30 °C and a flow rate of 250 μL/min. Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in 90% methanol. Bulk scan range: 67-1000 at 120,000 resolutions with 0.6 sec scan range. The 10 most intense ions in each full scan were selected for fragmentation and MS2 spectra were acquired at a resolution of 30,000 and scaled collision dissociation fragmentation energy of 25, 30, 35 was used. **UPLC** gradient. The total time used in the UPLC gradient runs was 15 minutes. The flow used was 0.250 mL/min and the following gradient in the percentage of mobile phase B was 50% at 8 min, 98% at 9 min. maintaining until a time of 13 min., ending with 0% between a time of 13.1 – 15 min.

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

Verification settings in the mass spectrum. The configurations used in the verification through the mass spectrum were orbit trap of the mass spectrum in the master scan, with an orbitrap detector with a resolution of 120,000. We used quadrupole isolation with a scanning range between 67-1000 m/z, using the frequency lens at 60%. The automatic gain control target was customized and normalized to 25%. The maximum injection time mode has been customized with a maximum injection time of 50 ms. MIcroscans of 1 and profile with positive polarity. Font fragmentation has been disabled. Data acquisition, metabolic identification, and data analysis. Once the data was acquired, the samples were analyzed using the open-source software MS-DIAL. More details about software obtained here: http://prime.psc.riken.jp/compms/msdial/main.html.^{59,60} Three blank samples were included in the analysis to identify background ions and remove them later. Samples acquired using MS1 full scan used for quantification and data-dependent acquisition (DDA) mode were used for spectral identification of metabolites. Tolerance MS1 was set to 0.01 Da and MS2 set to 0.025 Da. For peak harvesting, the mass slice width was set to 0.1. For peak alignment, the maximum retention time tolerance was set at 0.5 min, the MS1 tolerance was set at 0.01. Peaks were identified by searching MS2 spectra in the public MS-DIAL database downloaded in January 2023 (324,191 records for positive mode and 64,669 entries for negative mode) using a mass tolerance of 0.01 Da for MS1 and 0.05 Gives to MSMS with an identification cutoff point of 80% http://prime.psc.riken.jp/compms/msdial/main.html#MSP. Additionally, peaks were also searched against the core Biomolecular Analysis Facility's internal IROA library

(both positive and negative mode) with a mass tolerance of 0.02 and identification

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

cutoff of 85%. The data was manually inspected and identifications without MS2 were filtered, except for identifications of the IROA molecule. Supplementary Materials: The following supporting information: Figures S1-S7; Text S1; Text S2. Figure supplement legend: Figure S1 – Primer's specificity evaluation through Melting curve: (A) SHV, (B) KPC, (C) NDM, (D) TEM, (E) GES, (F) OXA-23like, (G) OXA-24/40like, (H) OXA-48like, (I) OXA-51like, (J) CTX-M 1.1like, (K) CTX-M 1.2like, (L) CTX-M 2like, (M) CTX-M 8like e (N) CTX-M 9like. Figure S2 - Plot analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae in general without separation by up- or down-regulation of the analytes. Note that in the supernatant of K. pneumoniae compared to the culture media, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased. Figure S3 - Plot of the analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae, separated because they were up-regulated in relation to the control culture media. Figure S4 - Plot of the analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae, separated because they were down-regulated in relation to the control culture media.

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

Figure S5 - Plot of the analyzes of the 25 main metabolites from the supernatant of Multidrug-Resistant (MDR) K. pneumoniae in general without separation by up- or down-regulation in the analytes. Note that in the intracellular media of K. pneumoniae compared to the culture medium, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased. Figure S6 - Plot of the analysis of the 25 main metabolites from the supernatant of K. pneumoniae MDR, separated by being up-regulated in relation to the control culture media. Figure S7 - Plot d of the analysis of the 25 main metabolites from the supernatant of K. pneumoniae MDR, separated because they were down-regulated in relation to the control culture media. **AUTHOR INFORMATION Corresponding Authors:** Aldo A.M. Lima - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, https://orcid.org/0000-0002-0299-1747 Email: <u>alima@ufc.br</u> José Kleybson de Sousa – Department of Pediatrics Gastroenterology, UVA Hospital, University Virginia, Charlottesville, Virginia 22903, United States; https://orcid.org/0000-0003-3512-484X

645 Email: <u>ztx7ex@virginia.edu;</u> 646 647 Authors 648 Lavouisier F.B. Nogueira - Institute of Biomedicine, Faculty of Medicine, Federal University 649 of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, 650 Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-5008-8181 651 652 Marília S. Maia - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, 653 Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department 654 Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, 655 https://orcid.org/0000-0002-7005-7841 656 Marco A.F Clementino - Institute of Biomedicine, Faculty of Medicine, Federal University of 657 Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, 658 Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. 659 https://orcid.org/0000-0002-0628-8047 660 Ila F.N. Lima - Hospital Universitário Walter Cantídio, Federal University of Ceara, 661 Fortaleza-Ceara 60430-270, Brazil. 662 Jorge L.N. Rodrigues - Hospital Universitário Walter Cantídio, Federal University of Ceara, 663 Fortaleza-Ceara 60430-270, Brazil. Luciana V.C. Fragoso - Hospital Universitário Walter Cantídio, Federal University of Ceara, 664 665 Fortaleza-Ceara 60430-270, Brazil.

It is made available under a CC-BY-ND 4.0 International license.

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

Glairta S. Costa - Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Jose Q.S. Filho - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-9619-4553 Alexandre Havt - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-4546-2976 Deiziane V.S. Costa - Infectious Diseases and International Health, University of Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0001-6402-8908 Lyvia M.V.C. Magalhães - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0001-6990-4903 Dilza Silva - Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesville, VA 22908. https://orcid.org/0000-0002-6519-346X Nicholas E. Sherman - Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesville, VA 22908. https://orcid.org/0000-0003-3206-3113 **Author Contributions:** Bibliographic review and data collection, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F Clementino and Aldo A.M. Lima.

686 Methodology, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F. 687 Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V. C. 688 Fragoso and Aldo A. M. Lima. 689 Bioinformatics, Lavouisier F.B. Nogueira and Marco A.F Clementino. 690 <u>In silico analyses</u>, Lavouisier F.B. Nogueira, Marco A.F Clementino. 691 In vitro validation of primers and sample testing, Lavouisier F.B. Nogueira, 692 Marília S. Maia. 693 Metabolomics, Datascience and data Bank, Jose Q.S. Filho; Deiziane V.S. Costa, 694 José K. Sousa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman and 695 Aldo A.M. Lima 696 Written review and editing, Lavouisier F.B. Nogueira. 697 Supervision, Alexandre Havt and Aldo A.M. Lima. 698 Project administration, Aldo A.M. Lima. 699 Resource acquisition, Aldo A.M. Lima. 700 701 Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers 702 402607/2018-0 and 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/), grant 703 number: OFÍCIO Nº 102/2021 – DINOV. 704 Acknowledge: This work used the following equipment's (Benchtop refrigerated 705 centrifuge 10k RPM Eppendorf; Speed Vac Thermo fisher; Bead Ruptor Elite Omni 706 International Material; Thermomixer Eppendorf; Orbitrap IDX spectrometer (Thermo) 707 connected to the Vanquish UPLC system) available in the Biomolecular Analysis Core 708 Facility which is supported by the University of Virginia School of Medicine, Research 709 Resource Identifiers (RRID):SCR 025476.

710

711 Data Availability Statement: The data and reports relating to this study will be 712 available via direct request via email to the corresponding author. 713 714 Conflicts of Interest: The authors declare that there are no financial or personal 715 conflicts of interest that may have influenced the work. 716 **REFERENCES** 717 718 (1) Munita, J. M.; Arias, C. A. Mechanisms of Antibiotic Resistance. Microbiol Spectr 2016, 4 719 (2). https://doi.org/10.1128/MICROBIOLSPEC.VMBF-0016-2015. 720 (2) Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. J Infect Public Health 2017, 10 (4), 721 369–378. https://doi.org/10.1016/J.JIPH.2016.08.007. 722 (3) Holt, K. E.; Wertheim, H.; Zadoks, R. N.; Baker, S.; Whitehouse, C. A.; Dance, D.; Jenney, 723 A.; Connor, T. R.; Hsu, L. Y.; Severin, J.; Brisse, S.; Cao, H.; Wilksch, J.; Gorrie, C.; Schultz, 724 M. B.; Edwards, D. J.; Van Nguyen, K.; Nguyen, T. V.; Dao, T. T.; Mensink, M.; Le Minh, 725 V.; Nhu, N. T. K.; Schultsz, C.; Kuntaman, K.; Newton, P. N.; Moore, C. E.; Strugnell, R. 726 A.; Thomson, N. R. Genomic Analysis of Diversity, Population Structure, Virulence, and 727 Antimicrobial Resistance in Klebsiella Pneumoniae, an Urgent Threat to Public Health. 728 Proc Natl Sci U S Α 2015, 112 Acad (27),E3574-E3581. 729 https://doi.org/10.1073/PNAS.1501049112/SUPPL_FILE/PNAS.1501049112.SD01.XLSX. 730 (4) Asri, N. A. M.; Ahmad, S.; Mohamud, R.; Hanafi, N. M.; Zaidi, N. F. M.; Irekeola, A. A.; 731 Shueb, R. H.; Yee, L. C.; Noor, N. M.; Mustafa, F. H.; Yean, C. Y.; Yusof, N. Y. Global 732 Prevalence of Nosocomial Multidrug-Resistant Klebsiella Pneumoniae: A Systematic 733 2021, 10 Review and Meta-Analysis. **Antibiotics** (12).734 https://doi.org/10.3390/ANTIBIOTICS10121508.

735 (5) Sharma, A.; Thakur, A.; Thakur, N.; Kumar, V.; Chauhan, A.; Bhardwaj, N. Changing 736 Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From 737 Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North 738 India. Cureus 2023, 15 (3). https://doi.org/10.7759/CUREUS.36317. 739 (6) Cortés, G.; Borrell, N.; De Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular 740 Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide 741 O Side Chain to the Virulence of Klebsiella Pneumoniae in a Murine Model of 742 Pneumonia. Infect Immun 2002, 70 (5), 2583-2590. https://doi.org/10.1128/IAI.70.5.2583-743 2590.2002/FORMAT/EPUB. 744 (7) Struve, C.; Bojer, M.; Krogfelt, K. A. Identification of a Conserved Chromosomal Region 745 Encoding Klebsiella Pneumoniae Type 1 and Type 3 Fimbriae and Assessment of the Role 746 Infect Fimbriae in Pathogenicity. Immun 2009, 77 (11),5016-5024. 747 https://doi.org/10.1128/IAI.00585-09/FORMAT/EPUB. 748 (8)Lin, C. T.; Chen, Y. C.; Jinn, T. R.; Wu, C. C.; Hong, Y. M.; Wu, W. H. Role of the CAMP-749 Dependent Carbon Catabolite Repression in Capsular Polysaccharide Biosynthesis in 750 Klebsiella Pneumoniae. PLoS2013, (2),e54430. 751 https://doi.org/10.1371/JOURNAL.PONE.0054430. 752 (9) Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. Microbiol Mol Biol 753 Rev 2010, 74 (3), 417. https://doi.org/10.1128/MMBR.00016-10. 754 (10)Salipante, S. J.; Jerome, K. R. Digital PCR-An Emerging Technology with Broad 755 Microbiology. 2020, 117–123. Applications in Clin Chem 66 (1),756 https://doi.org/10.1373/CLINCHEM.2019.304048. 757 (11)Fortuin, S.; Soares, N. C. The Integration of Proteomics and Metabolomics Data Paving 758 the Way for a Better Understanding of the Mechanisms Underlying Microbial Acquired

Drug Resistance. Frontiers in Medicine 2022, 9. https://doi.org/10.3389/fmed.2022.849838.

759

- 760 Zeng, C.; Tandhanskul, A.; Krungkaew, S.; Likhanapaiboon, T.; Kasayapanan, W.; (12)761 Yasurin, P.; Tang, J.; Phusantisampan, T.; Tawai, A. Research Progress on Using Omics 762 Technology to Examine the Antimicrobial Mechanisms of Natural Active Substances. 763 Applied Science Engineering **Progress** 2024. and 764 https://doi.org/10.14416/j.asep.2024.07.003. 765 (13)Bush, K.; Bradford, P. A. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med 2016, 6 (8). https://doi.org/10.1101/CSHPERSPECT.A025247. 766 767 Ferreira, A. M.; Martins, K. B.; Silva, V. R. da; Mondelli, A. L.; Cunha, M. de L. R. de S. da. (14)768 Correlation of Phenotypic Tests with the Presence of the BlaZ Gene for Detection of Beta-769 2017, 48 (1),159-166. Lactamase. Braz Microbiol 770 https://doi.org/10.1016/J.BJM.2016.10.011. 771 (15)Zhu, L. J.; Pan, Y.; Gao, C. Y.; Hou, P. F. Distribution of Carbapenemases and Efflux 772 Pump in Carbapenem-Resistance Acinetobacter Baumannii. Ann Clin Lab Sci 2020, 50 (2). 773 (16)Makharita, R. R.; El-Kholy, I.; Hetta, H. F.; Abdelaziz, M. H.; Hagagy, F. I.; Ahmed, A. A.; 774 Algammal, A. M. Antibiogram and Genetic Characterization of Carbapenem-Resistant 775 Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections. Infect Drug 776 Resist 2020, 13, 3991–4002. https://doi.org/10.2147/IDR.S276975. 777 (17)Santos, A. L.; Dos Santos, A. P.; Ito, C. R. M.; de Queiroz, P. H. P.; de Almeida, J. A.;
- 778 Júnior, M. A. B. de C.; de Oliveira, C. Z.; Avelino, M. A. G.; Wastowski, I. J.; Gomes, G. P.
- 779 L. A.; E Souza, A. C. S.; Vasconcelos, L. S. N. de O. L.; Santos, M. de O.; da Silva, C. A.;
- 780 Carneiro, L. C. Profile of Enterobacteria Resistant to Beta-Lactams. *Antibiotics* 2020, 9 (7),
- 781 1–18. https://doi.org/10.3390/ANTIBIOTICS9070410.
- 782 (18) Abdel-Rhman, S. H. Characterization of β-Lactam Resistance in K. Pneumoniae
- 783 Associated with Ready-to-Eat Processed Meat in Egypt. PLoS One 2020, 15 (9), e0238747.
- 784 https://doi.org/10.1371/JOURNAL.PONE.0238747.

785 (19)Messaoudi, A.; Mansour, W.; Jaidane, N.; Chaouch, C.; Boujaâfar, N.; Bouallègue, O. 786 Epidemiology of Resistance and Phenotypic Characterization of Carbapenem Resistance 787 Mechanisms in Klebsiella Pneumoniae Isolates at Sahloul University Hospital-Sousse, 788 Tunisia. Afr Health Sci 2019, 19 (2), 2008–2020. https://doi.org/10.4314/AHS.V19I2.24. 789 (20) Farhadi, M.; Ahanjan, M.; Goli, H. R.; Haghshenas, M. R.; Gholami, M. High Frequency of 790 Multidrug-Resistant (MDR) Klebsiella Pneumoniae Harboring Several β-Lactamase and 791 Integron Genes Collected from Several Hospitals in the North of Iran. Annals of Clinical 792 Microbiology and Antimicrobials **2021**, 20 (1). https://doi.org/10.1186/s12941-021-00476-1. 793 (21)Oliveira, R.; Castro, J.; Silva, S.; Oliveira, H.; Saavedra, M. J.; Azevedo, N. F.; Almeida, C. 794 Exploring the Antibiotic Resistance Profile of Clinical Klebsiella Pneumoniae Isolates in 795 Portugal. Antibiotics (Basel) 2022, 11 (11). https://doi.org/10.3390/ANTIBIOTICS11111613. 796 (22)Bush, K.; Bradford, P. A. Epidemiology of β-Lactamase-Producing Pathogens. Clin 797 Microbiol Rev 2020, 33 (2). https://doi.org/10.1128/CMR.00047-19. 798 (23)Castanheira, M.; Simner, P. J.; Bradford, P. A. Extended-Spectrum β-Lactamases: An 799 Update on Their Characteristics, Epidemiology and Detection. JAC Antimicrob Resist 2021, 800 3 (3). https://doi.org/10.1093/JACAMR/DLAB092. 801 (24)Gundran, R. S.; Cardenio, P. A.; Villanueva, M. A.; Sison, F. B.; Benigno, C. C.; 802 Kreausukon, K.; Pichpol, D.; Punyapornwithaya, V. Prevalence and Distribution of 803 BlaCTX-M, BlaSHV, BlaTEM Genes in Extended- Spectrum β- Lactamase- Producing E. 804 Coli Isolates from Broiler Farms in the Philippines. BMC Vet Res 2019, 15 (1). 805 https://doi.org/10.1186/S12917-019-1975-9. 806 (25)Queiroz, J. A. da S.; Alves, L. S.; Dall'acqua, D. S. V.; Souza, L. F. B.; Faculdades 807 Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Faculdades Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Fundação Oswaldo Cruz. Porto Velho, R. Brasil. / F. I. 808 809 A. Carvalho, P. V. R. Brasil.; Faculdades Integradas Aparício Carvalho, Porto Velho, R. 810 Brasil. Desenho e Validação de Primers In Silico Para Detecção Do Vírus Sincicial 811 Respiratório Humano. Revista FIMCA 2017, 4 (1), 17–30. 812 (26)Kumar, A.; Chordia, N. In Silico PCR Primer Designing and Validation. Methods Mol Biol 813 **2015**, 1275, 143–151. https://doi.org/10.1007/978-1-4939-2365-6 10. 814 (27)Rodríguez, A.; Rodríguez, M.; Córdoba, J. J.; Andrade, M. J. Design of Primers and Probes 815 for Quantitative Real-Time PCR Methods. *Methods in Molecular Biology* **2015**, 1275, 31–56. 816 https://doi.org/10.1007/978-1-4939-2365-6_3. 817 (28)van Weezep, E.; Kooi, E. A.; van Rijn, P. A. PCR Diagnostics: In Silico Validation by an 818 Automated Tool Using Freely Available Software Programs. J Virol Methods 2019, 270, 819 106–112. https://doi.org/10.1016/J.JVIROMET.2019.05.002. 820 (29)Yang, J.; Kemps-Mols, B.; Spruyt-Gerritse, M.; Anholts, J.; Claas, F.; Eikmans, M. The 821 Source of SYBR Green Master Mix Determines Outcome of Nucleic Acid Amplification 822 Reactions. BMC Res Notes 2016, 9 (1), 1-10. https://doi.org/10.1186/S13104-016-2093-823 4/FIGURES/4. 824 (30)Wang, Y.; Li, W.; Guo, X.; Zhang, D.; Sun, J.; Fu, Z.; Liu, G.; Li, Y.; Jiang, S. Development 825 of SYBR Green I-Based Polymerase Chain Reaction for Feline Bocavirus 1 Detection. 3 826 Biotech 2021, 11 (2). https://doi.org/10.1007/S13205-020-02577-8. 827 (31)Desriani; Azamris; Ghaissani, S. S.; Kinanti, S. R.; Warisman, M. A.; Fitria, N. Design and 828 Characterization of a SYBR Green I-Based Melting Curve Method for Investigation of 829 HER2I655V Polymorphism in Breast Cancer. J Genet Eng Biotechnol 2021, 19 (1). 830 https://doi.org/10.1186/S43141-020-00108-9. 831 (32)Svec, D.; Tichopad, A.; Novosadova, V.; Pfaffl, M. W.; Kubista, M. How Good Is a PCR 832 Efficiency Estimate: Recommendations for Precise and Robust QPCR Efficiency 833 Quantif 2015, 3, Assessments. Biomol Detect 9–16. 834 https://doi.org/10.1016/J.BDQ.2015.01.005.

835 PCR: US. (33)Thermo Fisher Scientific. Real-Time **Understanding** Ct836 https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-837 learning-center/real-time-pcr-basics/real-time-pcr-understanding-ct.html (accessed 2024-838 05-05). 839 (34)Han, R.; Shi, Q.; Wu, S.; Yin, D.; Peng, M.; Dong, D.; Zheng, Y.; Guo, Y.; Zhang, R.; Hu, F. 840 Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among 841 Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in 842 China. Front Cell Infect Microbiol 2020, 10, 314. https://doi.org/10.3389/FCIMB.2020.00314. 843 (35)Marschall, J.; Tibbetts, R. J.; Dunne, W. M.; Frye, J. G.; Fraser, V. J.; Warren, D. K. Presence 844 of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its 845 Correlation with In Vitro Carbapenem Susceptibility. J Clin Microbiol 2009, 47 (1), 239. 846 https://doi.org/10.1128/JCM.02123-08. 847 (36)Kharazmkia, A.; Amirizadeh, M.; Goudarzi, Z.; Birjandi, M.; Barfipoursalar, A.; Mir, S. 848 Prevalence of KPC-Producing Bacteria in Negative Gram of Clinical Samples Obtained 849 from 2022, 77, 103690. Patients. Annals Medicine Surgery of and 850 https://doi.org/10.1016/J.AMSU.2022.103690. 851 (37)Pawłowska, I.; Ziółkowski, G.; Jachowicz-Matczak, E.; Stasiowski, M.; Gajda, M.; 852 Wójkowska-Mach, J. Colonization and Healthcare-Associated Infection of Carbapenem-853 Resistant Enterobacteriaceae, Data from Polish Hospital with High Incidence of 854 Carbapenem-Resistant Enterobacteriaceae, Does Active Target Screening Matter? 855 Microorganisms 2023, 11 (2). https://doi.org/10.3390/MICROORGANISMS11020437. 856 (38)Ferreira, R. L.; da Silva, B. C. M.; Rezende, G. S.; Nakamura-Silva, R.; Pitondo-Silva, A.; 857 Campanini, E. B.; Brito, M. C. A.; da Silva, E. M. L.; Freire, C. C. de M.; Cunha, A. F. da; 858 Pranchevicius, M.-C. da S. High Prevalence of Multidrug-Resistant Klebsiella 859 Pneumoniae Harboring Several Virulence and β-Lactamase Encoding Genes in a 860 Brazilian 2019, 9. Intensive Care Unit. Frontiers in Microbiology 861 https://doi.org/10.3389/fmicb.2018.03198. 862 (39)Kernéis, S.; Lucet, J. C.; Santoro, A.; Meschiari, M. Individual and Collective Impact of 863 Klebsiella Pneumoniae Carbapenemase (KPC)-Producing K. Pneumoniae in Patients 864 Admitted to the ICU. J Antimicrob Chemother 2021, 76 (Suppl 1), I19-I26. https://doi.org/10.1093/JAC/DKAA494. 865 Dirar, M. H.; Bilal, N. E.; Ibrahim, M. E.; Hamid, M. E. Prevalence of Extended-Spectrum 866 (40)β-Lactamase (ESBL) and Molecular Detection of Bla TEM, Bla SHV and Bla CTX-M 867 868 Genotypes among Enterobacteriaceae Isolates from Patients in Khartoum, Sudan. Pan Afr 869 Med J 2020, 37, 1–11. https://doi.org/10.11604/PAMJ.2020.37.213.24988. 870 (41) Pavez, M.; Troncoso, C.; Osses, I.; Salazar, R.; Illesca, V.; Reydet, P.; Rodríguez, C.; 871 Chahin, C.; Concha, C.; Barrientos, L. High Prevalence of CTX-M-1 Group in ESBL-872 Producing Enterobacteriaceae Infection in Intensive Care Units in Southern Chile. Braz 1 873 Infect Dis 2019, 23 (2), 102–110. https://doi.org/10.1016/J.BJID.2019.03.002. 874 (42) Camargo, C. H.; Yamada, A. Y.; Souza, A. R. de; Reis, A. D.; Santos, M. B. N.; Assis, D. B. 875 de; Carvalho, E. de; Takagi, E. H.; Cunha, M. P. V.; Tiba-Casas, M. R. Genomic Diversity 876 of NDM-Producing Klebsiella Species from Brazil, 2013-2022. Antibiotics 2022, 11 (10), 877 1395.https://doi.org/10.3390/antibiotics11101395. 878 Vivas, R.; Dolabella, S. S.; Barbosa, A. A. T.; Jain, S. Prevalence of Klebsiella Pneumoniae 879 Carbapenemase - and New Delhi Metallo-Beta-Lactamase-Positive K. Pneumoniae in 880 Sergipe, Brazil, and Combination Therapy as a Potential Treatment Option. Revista da 881 Sociedade Brasileira de Medicina Tropical 2020, 53. https://doi.org/10.1590/0037-8682-0064-882 2020. 883 (44)Belouad, E. M.; Benaissa, E.; El Mrimar, N.; Bssaibis, F.; Maleb, A.; Elouennass, M. 884 Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan 885 Hospital. Int J Microbiol 2023, 2023. https://doi.org/10.1155/2023/8581883.

886 (45)Magagnin, C. M.; Rozales, F. P.; Antochevis, L.; Nunes, L. S.; Martins, A. S.; Barth, A. L.; 887 Sampaio, J. M.; Zavascki, A. P. Dissemination of Bla OXA-370 Gene among Several 888 Enterobacteriaceae Species in Brazil. Eur J Clin Microbiol Infect Dis 2017, 36 (10), 1907-889 1910. https://doi.org/10.1007/S10096-017-3012-X. 890 (46)Evans, B. A.; Amyes, S. G. B. OXA β-Lactamases. Clin Microbiol Rev 2014, 27 (2), 241–263. 891 https://doi.org/10.1128/CMR.00117-13/ASSET/DF7BB1F6-F6E8-4208-8829-892 B01CD28A0242/ASSETS/GRAPHIC/ZCM9990924610006.JPEG. 893 (47)Shahid, M.; Ahmad, N.; Saeed, N. K.; Shadab, M.; Joji, R. M.; Al-Mahmeed, A.; Bindayna, 894 K. M.; Tabbara, K. S.; Dar, F. K. Clinical Carbapenem-Resistant Klebsiella Pneumoniae 895 Isolates Simultaneously Harboring Bla NDM-1, Bla OXA Types and QnrS Genes from the 896 Kingdom of Bahrain: Resistance Profile and Genetic Environment. Front Cell Infect 897 Microbiol 2022, 12. https://doi.org/10.3389/FCIMB.2022.1033305. 898 (48)Manandhar, S.; Zellweger, R. M.; Maharjan, N.; Dongol, S.; Prajapati, K. G.; Thwaites, G.; 899 Basnyat, B.; Dixit, S. M.; Baker, S.; Karkey, A. A High Prevalence of Multi-Drug Resistant 900 Gram-Negative Bacilli in a Nepali Tertiary Care Hospital and Associated Widespread 901 Distribution of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-902 Encoding Genes. Clin Microbiol Antimicrob 2020, 19 (1),1–13. Ann 903 https://doi.org/10.1186/S12941-020-00390-Y/FIGURES/5. 904 (49)Awosile, B. B.; Agbaje, M.; Adebowale, O.; Kehinde, O.; Omoshaba, E. Beta-Lactamase 905 Resistance Genes in Enterobacteriaceae from Nigeria. Afr J Lab Med 2022, 11 (1). 906 https://doi.org/10.4102/AJLM.V11I1.1371. 907 (50)Han, M. L.; Nang, S. C.; Lin, Y. W.; Zhu, Y.; Yu, H. H.; Wickremasinghe, H.; Barlow, C. K.; 908 Creek, D. J.; Crawford, S.; Rao, G.; Dai, C.; Barr, J. J.; Chan, K.; Turner Schooley, R.; 909 Velkov, T.; Li, J. Comparative Metabolomics Revealed Key Pathways Associated with the 910 Synergistic Killing of Multidrug-Resistant Klebsiella Pneumoniae by a Bacteriophage911 Polymyxin Combination. Comput Struct Biotechnol 2022, 20, 485-495. 912 https://doi.org/10.1016/J.CSBJ.2021.12.039. (51)913 Kumar, A.; Singh, S.; Gupta, S. K.; Kumar, S.; Kumar, S.; Singh, R.; Thakur, L.; Kumar, M.; 914 Kapil, A.; Kumar, Y.; Kumar, N. Identification of Metabolite Extraction Method for 915 Targeted Exploration of Antimicrobial Resistance Associated Metabolites of Klebsiella 916 Pneumoniae. Sci Rep 2022, 12 (1). https://doi.org/10.1038/S41598-022-12153-0. 917 (52)Hudson, A. W.; Barnes, A. J.; Bray, A. S.; Ornelles, D. A.; Zafar, M. A. Klebsiella 918 Pneumoniae L-Fucose Metabolism Promotes Gastrointestinal Colonization 919 Modulates Its Virulence Determinants. Infect Immun 2022, 90 (10).920 https://doi.org/10.1128/IAI.00206-22. 921 (53)Lin, D.; Fan, J. M.; Wang, J.; Liu, L.; Xu, L.; Li, F.; Yang, J.; Li, B. The Fructose-Specific 922 Phosphotransferase System of Klebsiella Pneumoniae Is Regulated by Global Regulator and Linked to Virulence and Growth. Infect Immun 2018, 923 924 https://doi.org/10.1128/IAI.00340-18. 925 (54) Aminov, R. Metabolomics in Antimicrobial Drug Discovery. Expert Opinion on Drug 926 Discovery 2022, 17 (9), 1047–1059. https://doi.org/10.1080/17460441.2022.2113774. 927 (55) Kok, M.; Maton, L.; van der Peet, M.; Hankemeier, T.; van Hasselt, J. G. C. Unraveling 928 Antimicrobial Resistance Using Metabolomics. Drug Discovery Today 2022, 27 (6), 1774-929 1783. https://doi.org/10.1016/j.drudis.2022.03.015. 930 Soni, V.; Wang, Z.; Singh, V. Editorial: Bacterial Metabolomics Approach towards 931 Antimicrobials Resistance. Microbiology 2023, 14. and Frontiers in 932 https://doi.org/10.3389/fmicb.2023.1222594. 933 (57) Abril, A. G.; Quintela-Baluja, M.; Villa, T. G.; Calo-Mata, P.; Barros-Velázquez, J.; Carrera, 934 M. Proteomic Characterization of Virulence Factors and Related Proteins in Enterococcus 935 Strains from Dairy and Fermented Food Products. International Journal of Molecular

Sciences 2022, 23 (18), 10971. https://doi.org/10.3390/ijms231810971.

936

It is made available under a CC-BY-ND 4.0 International license .

| 937 | (58) | Azhar, F.; Busharat, M.; Chaudhary, S. R.; Waheed, Z.; Jamil, M. Metabolomics in Drug |
|-----|------|---|
| 938 | | Discovery: Restoring Antibiotic Pipeline. Asian Pacific Journal of Tropical Biomedicine 2023, |
| 939 | | 13 (9), 378. https://doi.org/10.4103/2221-1691.385568. |
| 940 | (59) | Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.; |
| 941 | | Vandergheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-Independent MS/MS |
| 942 | | Deconvolution for Comprehensive Metabolome Analysis. Nature Methods 2015 12:6 2015, |
| 943 | | 12 (6), 523–526. https://doi.org/10.1038/nmeth.3393. |
| 944 | (60) | Tsugawa, H.; Nakabayashi, R.; Mori, T.; Yamada, Y.; Takahashi, M.; Rai, A.; Sugiyama, |
| 945 | | R.; Yamamoto, H.; Nakaya, T.; Yamazaki, M.; Kooke, R.; Bac-Molenaar, J. A.; Oztolan- |
| 946 | | Erol, N.; Keurentjes, J. J. B.; Arita, M.; Saito, K. A Cheminformatics Approach to |
| 947 | | Characterize Metabolomes in Stable-Isotope-Labeled Organisms. Nat Methods 2019, 16 (4), |
| 948 | | 295–298. https://doi.org/10.1038/S41592-019-0358-2. |
| 949 | | |